Latest News

The 100% response rate for the combination was achieved in older patients with locally advanced or metastatic head and neck squamous cell carcinoma.

The ADMIRE study specifically enrolls patients with cutaneous squamous cell carcinoma who would otherwise be excluded from trials due to organ transplant or other immunocompromised state.

Phase 1 TRAVERSE results show that off-the-shelf CD70 CAR T ALLO-316 drives durable responses in refractory clear cell kidney cancer, with manageable safety signals.

Ten-year RELEVANCE results show chemo-free R2 matches immunochemotherapy for advanced follicular lymphoma, with comparable survival and safety.

The ENDURANCE study showed no difference in overall survival between 2 years of lenalidomide and indefinite treatment in standard-risk patients who did not receive autologous stem cell transplant.

The designation for pelareorep was supported by results from the phase 1/2 GOBLET study.

Phase 2 KEYPAD shows pembrolizumab plus denosumab yields 31% responses and 7.5-month PFS in VEGFR-TKI–pretreated clear-cell RCC.

During a live event, Millie Das, MD, and participants discussed how long-term survival data are reshaping first-line treatment selection for patients with PD-L1–negative metastatic non–small cell lung cancer.

Phase 2 data show safusidenib drives deepening responses and durable control in IDH1‑mutant grade 2 glioma, prompting new trials for earlier and post‑vorasidenib use.

TREASURE trial shows adding thoracic radiotherapy to atezolizumab maintenance in ES‑SCLC boosts fatal toxicity without survival gain.

Five-year WSG TP-II results suggest chemo-free endocrine therapy with dual HER2 blockade matches paclitaxel, with fewer severe side effects.

ENHANCE phase 3 results show that magrolimab added to azacitidine failed to boost remission or survival in higher-risk MDS and increased serious toxicity.

Long OMNIVORE follow-up shows select advanced RCC responders stop nivolumab and stay treatment-free for years; salvage ipilimumab adds little.

Chronic stress biomarker allostatic load links to higher under-50 cancer risk, offering a simple lab-based tool to improve prevention and screening.

During a live event, Matthew Rettig, MD, examined treatment options for a patient who had received prior doublet therapy for metastatic castration-resistant prostate cancer.

Early trial shows off-the-shelf immunotherapy combo boosts responses in relapsed B-cell lymphoma with manageable CRS and safety.

The phase 2 OPTIMAL-e trial combines the PSMA-targeted radioligand therapy with standard ADT and ARPI in metastatic hormone-sensitive prostate cancer.

Adding investigational BPM31510 to standard chemoradiation may boost survival in newly diagnosed glioblastoma, especially MGMT-unmethylated tumors, with promising safety data.

The Himalayas-1 trial will investigate rinzimetostat in combination with darolutamide in patients who previously received abiraterone for metastatic castration-resistant prostate cancer.

INVINCIBLE-4 restarts testing intratumoral INT230-6 before neoadjuvant pembrolizumab chemotherapy in early TNBC, aiming to boost pCR while reducing severe side effects.

A phase 1 trial of the radiotherapeutic determined a recommended phase 2 dose after promising activity in heavily pretreated multiple myeloma.

A trend toward improvement in overall survival (OS) with pembrolizumab was observed; however, the OS data are not mature.

National BRFSS study reveals SOGI adults lag in cervical and breast cancer screening; gaps are linked to insurance, access, and stigma.

During an event, Julia Rotow, MD, and participants discussed how a real-world case of cascading anemia and thrombocytopenia shifted the group's thinking on multilineage prophylaxis for extensive-stage small cell lung cancer.

Real-world data link vitamin D supplements to longer watch-and-wait time before CLL treatment, prompting fresh debate on delaying progression.

Phase 3 data show TROP2 ADC sac-TMT plus pembrolizumab extends PFS in PD-L1–negative nonsquamous NSCLC, signaling a new first-line option.

Tucidinostat plus nivolumab extends progression-free survival in treatment-naive advanced melanoma, offering a promising oral, chemo-free boost to frontline immunotherapy.

Oncologists debate BTK inhibitor choices in relapsed CLL, exploring when MRD testing matters, toxicity management, and insurance hurdles.

Phase 3 VIKTORIA-1 results show that gedatolisib combinations extend progression-free survival in PIK3CA-mutated breast cancer, with strong response rates and manageable stomatitis.

FDA gives full approval to selpercatinib for RET fusion solid tumors, backed by 47% response rate and long-lasting benefit across cancers.

Analyses of the CASSIOPEIA trial showed that some patients' outcomes could be associated with disease features besides depth of response alone.